207 related articles for article (PubMed ID: 18664951)
1. Assessing efficiency and costs of scaling up HIV treatment.
Cleary SM; McIntyre D; Boulle AM
AIDS; 2008 Jul; 22 Suppl 1():S35-42. PubMed ID: 18664951
[TBL] [Abstract][Full Text] [Related]
2. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
Bishai D; Colchero A; Durack DT
AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
[TBL] [Abstract][Full Text] [Related]
3. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
4. The economics of effective AIDS treatment in Thailand.
Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
[TBL] [Abstract][Full Text] [Related]
5. Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing.
Quentin W; König HH; Schmidt JO; Kalk A
Trop Med Int Health; 2008 Oct; 13(10):1245-56. PubMed ID: 18721185
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).
Beck EJ; Mandalia S; Youle M; Brettle R; Fisher M; Gompels M; Kinghorn G; McCarron B; Pozniak A; Tang A; Walsh J; Williams I; Gazzard B
Int J STD AIDS; 2008 May; 19(5):297-304. PubMed ID: 18482958
[TBL] [Abstract][Full Text] [Related]
7. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.
Jordan MR; Bennett DE; Bertagnolio S; Gilks CF; Sutherland D
Antivir Ther; 2008; 13 Suppl 2():15-23. PubMed ID: 18575188
[TBL] [Abstract][Full Text] [Related]
8. 'Time is costly': modelling the macroeconomic impact of scaling-up antiretroviral treatment in sub-Saharan Africa.
Ventelou B; Moatti JP; Videau Y; Kazatchkine M
AIDS; 2008 Jan; 22(1):107-13. PubMed ID: 18090398
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.
Long EF; Brandeau ML; Galvin CM; Vinichenko T; Tole SP; Schwartz A; Sanders GD; Owens DK
AIDS; 2006 Nov; 20(17):2207-15. PubMed ID: 17086061
[TBL] [Abstract][Full Text] [Related]
10. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
Marseille E; Saba J; Muyingo S; Kahn JG
AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
[TBL] [Abstract][Full Text] [Related]
11. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico.
Aracena-Genao B; Navarro JO; Lamadrid-Figueroa H; Forsythe S; Trejo-Valdivia B
AIDS; 2008 Jul; 22 Suppl 1():S141-8. PubMed ID: 18664946
[TBL] [Abstract][Full Text] [Related]
12. Equity and efficiency in HIV-treatment in South Africa: the contribution of mathematical programming to priority setting.
Cleary S; Mooney G; McIntyre D
Health Econ; 2010 Oct; 19(10):1166-80. PubMed ID: 19725025
[TBL] [Abstract][Full Text] [Related]
13. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.
Bennett DE; Bertagnolio S; Sutherland D; Gilks CF
Antivir Ther; 2008; 13 Suppl 2():1-13. PubMed ID: 18578063
[TBL] [Abstract][Full Text] [Related]
14. Public-sector ART in the Free State Province, South Africa: community support as an important determinant of outcome.
Wouters E; Van Damme W; Van Loon F; van Rensburg D; Meulemans H
Soc Sci Med; 2009 Oct; 69(8):1177-85. PubMed ID: 19692165
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of group psychotherapy for depression in Uganda.
Siskind D; Baingana F; Kim J
J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
[TBL] [Abstract][Full Text] [Related]
16. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens.
Renaud-Théry F; Nguimfack BD; Vitoria M; Lee E; Graaff P; Samb B; Perriëns J
AIDS; 2007 Jul; 21 Suppl 4():S89-95. PubMed ID: 17620758
[TBL] [Abstract][Full Text] [Related]
17. Costs associated with combination antiretroviral therapy in HIV-infected patients.
Yazdanpanah Y
J Antimicrob Chemother; 2004 Apr; 53(4):558-61. PubMed ID: 14985277
[TBL] [Abstract][Full Text] [Related]
18. Differences in normal activities, job performance and symptom prevalence between patients not yet on antiretroviral therapy and patients initiating therapy in South Africa.
Rosen S; Ketlhapile M; Sanne I; Desilva MB
AIDS; 2008 Jul; 22 Suppl 1():S131-9. PubMed ID: 18664945
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand.
Ono S; Kurotaki T; Nakasone T; Honda M; Boon-Long J; Sawanpanyalert P; Kimura K
Jpn J Infect Dis; 2006 Jun; 59(3):168-73. PubMed ID: 16785697
[TBL] [Abstract][Full Text] [Related]
20. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.
Desai K; Sansom SL; Ackers ML; Stewart SR; Hall HI; Hu DJ; Sanders R; Scotton CR; Soorapanth S; Boily MC; Garnett GP; McElroy PD
AIDS; 2008 Sep; 22(14):1829-39. PubMed ID: 18753932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
